FY19
12
|
FY18
17
|
FY17
2
|
FY16
43
|
FY19
-0.041
|
FY18
-0.075
|
FY17
-0.198
|
FY16
-0.020
|
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.